Ebert Ellen C, Geng Xin, Lin Jim, Das Kiron M
Crohn's and Colitis Center of NJ, Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, 1 Robert Wood Johnson Place, MEB 478, New Brunswick, NJ 08903, USA.
Cell Immunol. 2006 Nov;244(1):43-9. doi: 10.1016/j.cellimm.2007.02.004. Epub 2007 Apr 9.
Patients with ulcerative colitis (UC) have IgG1 antibodies in serum and colon against human tropomyosin isoform 5 (hTM5), a cytoskeletal microfilament protein found intracellularly and on the surface of colonic epithelial cells (EC). These antibodies may be pathogenic in UC.
Sera from patients with UC (n=110) or Crohn's disease (CD) (n=50) and from healthy individuals (Hl) (n=30) were preincubated with recombinant hTM5 or bovine serum albumin (BSA), then cultured for 4h with (51)Cr-labelled colonic adenocarcinoma cells (LS180). Cytotoxicity was determined by (51)Cr release assay.
All serum samples lysed up to 36% of LS180 cells regardless of the source of the serum. However, adding hTM5 to UC, but not to CD or HI, sera reduced cytotoxicity by up to 75%. This hTM5-induced inhibition of cytotoxicity was found especially with sera from UC patients with active disease, and was found even after total colectomy. The hTM5-induced inhibition was mediated by purified IgG from UC sera. Complement was involved since hTM5-induced inhibition of cytotoxicity declined with either heat inactivation of the sera or premixing sera with Fc fragments.
This study shows that hTM5-specific IgG autoantibodies present in UC sera destroy LS180 cells by antibody and complement-mediated lysis. Such a phenomenon was not seen in CD or HI. This suggests an autoantigenic role of hTM5 and anti-hTM5 antibodies in the pathogenesis of UC. This observation may lead to novel diagnostic and therapeutic possibilities.
溃疡性结肠炎(UC)患者血清及结肠中存在针对人原肌球蛋白亚型5(hTM5)的IgG1抗体,hTM5是一种存在于细胞内及结肠上皮细胞(EC)表面的细胞骨架微丝蛋白。这些抗体可能在UC中具有致病性。
将UC患者(n = 110)、克罗恩病(CD)患者(n = 50)及健康个体(Hl)(n = 30)的血清与重组hTM5或牛血清白蛋白(BSA)预孵育,然后与(51)Cr标记的结肠腺癌细胞(LS180)培养4小时。通过(51)Cr释放试验测定细胞毒性。
无论血清来源如何,所有血清样本均可裂解高达36%的LS180细胞。然而,向UC血清中添加hTM5可使细胞毒性降低高达75%,而向CD或Hl血清中添加则无此作用。这种hTM5诱导的细胞毒性抑制尤其在活动期UC患者的血清中发现,甚至在全结肠切除术后仍可发现。hTM5诱导的抑制作用由UC血清中的纯化IgG介导。补体参与其中,因为hTM5诱导的细胞毒性抑制随着血清热灭活或血清与Fc片段预混合而降低。
本研究表明,UC血清中存在的hTM5特异性IgG自身抗体通过抗体和补体介导的裂解作用破坏LS180细胞。在CD或Hl中未观察到这种现象。这表明hTM5和抗hTM5抗体在UC发病机制中具有自身抗原作用。这一观察结果可能带来新的诊断和治疗可能性。